stockrowRelay Therapeutics, Inc.
RLAY Healthcare Biotechnology
Relay Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.4 million, up 53.4% from fiscal 2024.
- Revenue
- −95.4%
- EPS
- 0.00%
- Free cash flow
- +2.13%
Quarter to June 2026, against a year earlier
Follow RLAY
Alert me
Relay Therapeutics, Inc. (RLAY) EPS (diluted)
Relay Therapeutics, Inc.'s EPS (diluted) for fiscal 2025 was −$1.61, compared with −$2.36 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.57. Over the past ten years it has ranged from −$21.82 (fiscal 2019) to −$0.54 (fiscal 2018); the current reading is higher than 88% of that period. Relay Therapeutics, Inc. ranks 278th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.61 | — |
| FY2024 | −$2.36 | — |
| FY2023 | −$2.79 | — |
| FY2022 | −$2.59 | — |
| FY2021 | −$3.82 | — |
| FY2020 | −$5.40 | — |
| FY2019 | −$21.82 | — |
| FY2018 | −$0.54 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.41 | — |
| Mar 2026 | −$0.41 | — |
| Dec 2025 | −$0.32 | — |
| Sep 2025 | −$0.43 | — |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $2.11 |
| IOVA Iovance Biotherapeutics, Inc. compare | −$0.53 |
| ABCL AbCellera Biologics Inc. compare | −$0.54 |
| TNGX Tango Therapeutics, Inc. compare | −$0.85 |
| RLAY Relay Therapeutics, Inc. | −$1.57 |
| EWTX Edgewise Therapeutics, Inc. compare | −$1.85 |
| XENE Xenon Pharmaceuticals Inc. compare | −$4.74 |
| IRON Disc Medicine, Inc. compare | −$6.58 |
| PBLS Parabilis Medicines, Inc. compare | −$83.02 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on RLAY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement